TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2395.
Locate Jan Aushadhi KendraClinical Overview
Baricitinib is an oral selective and reversible Janus kinase 1 and 2 (JAK1/JAK2) inhibitor. By inhibiting the JAK-STAT pathway, it blocks signaling of pro-inflammatory cytokines (IL-6, IFN-gamma, GM-CSF). In infectious diseases, it acts as an immunomodulatory antiviral adjuvant in hospitalized COVID-19 patients requiring oxygen support, mitigating life-threatening hyperinflammatory cytokine storms. Also indicated for severe rheumatoid arthritis and alopecia areata.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with or without food. In hospitalized COVID-19 protocols, typically prescribed for 14 days or until hospital discharge. Follow specialist's dosing recommendations based on renal clearance.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Upper respiratory tract infections, nausea, headache, elevated cholesterol levels, herpes simplex/zoster flares. Rare/Severe: Serious bacterial/fungal infections, deep vein thrombosis (DVT) and pulmonary embolism (PE), major adverse cardiovascular events (MACE), malignancies, and bowel perforation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warnings: Serious infections, all-cause mortality, cardiovascular events, thrombosis, and malignancies. Screen for latent tuberculosis and viral hepatitis prior to use. Contraindicated in absolute lymphocyte count < 500, absolute neutrophil count < 1000, or hemoglobin < 8 g/dL.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.